<DOC>
	<DOC>NCT01780428</DOC>
	<brief_summary>This is a double-blind, randomized, multiple-dose, placebo- and positive-controlled study of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) in patients with moderate to severe pain following surgical removal of impacted third molar teeth. A positive control ( Norco, a commercial formulation of hydrocodone 7.5 mg/APAP 325 mg) was included to determine the anti-emetic effects of CL-108. The efficacy of CL-108 was also evaluated to placebo for the relief of pain.</brief_summary>
	<brief_title>Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>Determination of being likely or possibly nauseaprone. Male or nonpregnant and nonlactating female. Surgical extraction of at least 2 impacted third molar teeth A female of childbearing potential is eligible to participate in this study if she has a negative urine pregnancy test and is using an acceptable method of birth control. Surgical extraction of at least 2 impacted third molar teeth. Presence of at least moderate postoperative pain. Medial Condition, presence of a serious medical condition. Active local infection. Drug Allergy history of hypersensitivity to an Opioid, Promethazine, Acetaminophen. Caffeine use since midnight before the operation. Use of an IND Drug within past 30 days. Previous participation in this study. Pregnant or lactating. Employee of the PI,subinvestigator or Charleston Labs or relative of an employee.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>